Healthcare Services

Liver Diseases Therapeutics Market Forecast Through 2030 Featuring Industry Drivers And Opportunities

June 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Increase In Market Value Is Predicted For The Liver Diseases Therapeutics Market During The 2026–2030 Period?

The liver diseases therapeutics market has demonstrated robust expansion in recent years. This sector is projected to increase from $15.18 billion in 2025 to $16.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.8%. The historical growth can be attributed to the high prevalence of viral hepatitis infections, increasing alcohol-induced liver disease cases, early reliance on antiviral and supportive therapies, limited treatment options for chronic liver conditions, and growing hospital-based liver care.

The liver diseases therapeutics market size is projected for substantial expansion over the next few years. It is forecast to grow to $24.27 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.9%. This growth in the forecast period is primarily attributed to factors such as the increasing burden of metabolic liver diseases, the growing adoption of immunosuppressive and targeted therapies, the expansion of liver cancer treatment pipelines, rising awareness of the benefits of early treatment, and increased healthcare spending on chronic liver diseases. Major trends expected during this period include a rising demand for antiviral therapies in hepatitis treatment, an increasing focus on NAFLD and NASH management, the growing adoption of immunotherapy in liver cancer, the expansion of combination drug therapies, and an enhanced emphasis on long-term disease management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp

What Are The Main Drivers Accelerating The Growth Of The Liver Diseases Therapeutics Market?

The growing incidence of liver conditions is anticipated to fuel the expansion of the liver disease therapeutics market moving forward. Liver disease refers to any ailment affecting the liver. Liver disease therapeutics aid in managing liver conditions through various treatment methods. For example, in December 2024, the Office for Health Improvement and Disparities, a UK-based government department, reported that in 2023, premature deaths due to alcoholic liver disease escalated by 3.6%, reaching 5,984, an increase from 5,776 in 2022. Thus, the increasing occurrence of liver diseases is a key driver for the growth of the liver disease therapeutics market.

Which Segment-Based Categories Are Covered In The Liver Diseases Therapeutics Market?

The liver diseases therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer

2) By Treatment: Antiviral, Chemotherapy, Immunosuppressive Agents, Corticosteroids

3) By End User: Hospitals, Ambulatory Surgery Centers

Subsegments:

1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D

2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver

3) By Alcohol-Induced: Alcoholic Hepatitis, Alcoholic Cirrhosis

4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma

Which Trends Are Guiding The Development Of The Liver Diseases Therapeutics Market?

Leading companies operating in the liver disease therapeutics market are concentrating on innovative technologies, such as artificial intelligence, to support clinicians in identifying patients with liver fibrosis early in their disease progression. Artificial intelligence in liver disease therapeutics involves utilizing advanced computational algorithms and machine learning techniques to analyze medical data, thereby assisting in early detection, diagnosis, and personalized treatment strategies for liver diseases. For instance, in February 2023, Predictive Health Intelligence, a UK-based healthcare information management company, introduced hepatoSIGHT. hepatoSIGHT is an innovative AI-powered tool capable of predicting liver fibrosis in patients with chronic liver disease, serving as a case-finding and cohort mapping utility designed to pinpoint individuals at risk of Chronic Liver Disease (CLD). It functions as a secure, intuitive, and easy-to-use system that can rapidly review millions of data points to identify patients who meet specified criteria. Moreover, its features include comprehensive data analysis, machine learning algorithms, real-time risk stratification, and a user-friendly interface.

Which Industry Players Are Present In The Liver Diseases Therapeutics Market?

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

Access The Complete Liver Diseases Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Which Area Represents The Largest Portion Of The Liver Diseases Therapeutics Market?

North America was the largest region in the liver diseases therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Liver Diseases Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=7969&type=smp

Browse Through More Reports Similar to the Global Liver Diseases Therapeutics Market 2026, By The Business Research Company

Hepatitis Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Liver Health Supplements Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/liver-health-supplements-global-market-report

Fatty Liver Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795